News

A new study has compared Wegovy and Zepbound head-to-head in their ability to treat obesity. People taking Eli Lilly’s ...
"We are introducing Wegovy (injectable Semaglutide 2.4 mg) this year, which offers full therapeutic strengths of semaglutide ...
With VKTX surging on clinical results and NVO investing to cement market share, investors face a high-stake GLP-1 showdown.
Just 14 stocks with market caps above $1 billion have doubled so far this year. They probably aren't the winners you would ...
FAT JABS have taken the nation’s waistline by storm – trimming inches and helping thousands shed weight, and fast. But it ...
Whichever way the tariff winds blow (and I've no special knowledge of that), Novo Nordisk stock remains arguably the cheapest ...
The MUSC Weight Management Center (WMC) is casting a lifeline to plus-sized individuals at wit's end with their apple cider ...
A new study has pitted Wegovy and Zepbound head-to-head in their ability to treat obesity. Published in The New England ...
Access remains limited to these effective but expensive drugs, even for patients covered by Medicaid, because of stringent prerequisites that must be satisfied before starting the drug.
Our writer takes a look at three red-hot growth stocks that have more than doubled this year to see if any of them interest ...
Veru's pivot with enobosarm: groundbreaking Phase 2b results enhance GLP-1 therapy outcomes. A positive launch could yield ...
A U.S. senator is asking the FDA how it will enforce regulations on pharmaceutical advertising after it let go of numerous ...